Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 4
2001 2
2002 4
2003 3
2004 11
2005 5
2006 9
2007 7
2008 1
2009 3
2010 3
2011 5
2012 4
2013 1
2014 1
2015 1
2016 2
2017 2
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.
Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanasis-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: gika d. Leuk Lymphoma. 2019 Mar;60(3):619-628. doi: 10.1080/10428194.2018.1509323. Epub 2019 Jan 10. Leuk Lymphoma. 2019. PMID: 30628505
Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Dimopoulos MA, et al. Among authors: gika d. J Clin Oncol. 2002 May 1;20(9):2327-33. doi: 10.1200/JCO.2002.09.039. J Clin Oncol. 2002. PMID: 11981004 Clinical Trial.
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.
Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Gika D, Fotiou D, Kanellias N, Ziogas DC, Ntanasis-Stathopoulos I, Mparmparousi D, Gatou A, Katopi D, Manios E, Liontos M, Giannouli S, Tsirigotis P, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: gika d. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):445-452. doi: 10.1016/j.clml.2019.10.014. Epub 2020 Feb 4. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32284296
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
Gavriatopoulou M, García-Sanz R, Kastritis E, Morel P, Kyrtsonis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: gika d. Blood. 2017 Jan 26;129(4):456-459. doi: 10.1182/blood-2016-09-742411. Epub 2016 Nov 21. Blood. 2017. PMID: 27872060 Free article. Clinical Trial.
Thalidomide and dexamethasone combination for refractory multiple myeloma.
Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Dimopoulos MA, et al. Among authors: gika d. Ann Oncol. 2001 Jul;12(7):991-5. doi: 10.1023/a:1011132808904. Ann Oncol. 2001. PMID: 11521808 Free article. Clinical Trial.
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group. Zagouri F, et al. Among authors: gika d. Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26. Eur J Haematol. 2017. PMID: 28675766
66 results